RenalytixAI: Thomas McLain

RenalytixAI has appointed Thomas McLain its president and chief commercial officer, effective immediately. He most recently was general manager, president, CEO, and chief operating officer for Exosome Diagnostics, where led the business and commercial strategy for the ExosomeDx Prostate test. The company was acquired by Bio-Techne in August 2018. Prior to that, McLain was president and CEO of Vermillion.